DexCom (DXCM) & LeMaitre Vascular (LMAT) Head to Head Comparison

DexCom (NASDAQ:DXCM) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.

Profitability

This table compares DexCom and LeMaitre Vascular’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DexCom -0.65% -7.45% -3.48%
LeMaitre Vascular 20.52% 18.49% 16.19%

Insider and Institutional Ownership

79.8% of LeMaitre Vascular shares are owned by institutional investors. 1.8% of DexCom shares are owned by company insiders. Comparatively, 20.3% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares DexCom and LeMaitre Vascular’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DexCom $718.50 million 15.86 -$50.20 million ($0.58) -222.41
LeMaitre Vascular $100.87 million 5.37 $17.17 million $0.86 32.62

LeMaitre Vascular has lower revenue, but higher earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for DexCom and LeMaitre Vascular, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom 0 6 13 0 2.68
LeMaitre Vascular 0 4 3 0 2.43

DexCom currently has a consensus target price of $127.67, indicating a potential downside of 1.03%. LeMaitre Vascular has a consensus target price of $36.14, indicating a potential upside of 28.85%. Given LeMaitre Vascular’s higher probable upside, analysts plainly believe LeMaitre Vascular is more favorable than DexCom.

Dividends

LeMaitre Vascular pays an annual dividend of $0.28 per share and has a dividend yield of 1.0%. DexCom does not pay a dividend. LeMaitre Vascular pays out 32.6% of its earnings in the form of a dividend. LeMaitre Vascular has raised its dividend for 2 consecutive years.

Risk and Volatility

DexCom has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.

Summary

LeMaitre Vascular beats DexCom on 12 of the 17 factors compared between the two stocks.

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

About LeMaitre Vascular

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply